Show simple item record

dc.contributor.authorMcKinney, P
dc.contributor.authorCartwright, R
dc.contributor.authorStiller, C
dc.contributor.authorHopton, P
dc.contributor.authorMann, J
dc.contributor.authorBirch, Jillian M
dc.contributor.authorHartley, Ann L
dc.contributor.authorWaterhouse, J
dc.contributor.authorJohnston, H
dc.date.accessioned2010-12-02T16:56:15Z
dc.date.available2010-12-02T16:56:15Z
dc.date.issued1985-12
dc.identifier.citationInter-Regional Epidemiological Study of Childhood Cancer (IRESCC): childhood cancer and the consumption of debendox and related drugs in pregnancy. 1985, 52 (6):923-9 Br J Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid4074645
dc.identifier.urihttp://hdl.handle.net/10541/116988
dc.description.abstractAttention has recently focused on the possible teratogenic effects of the combination antiemetic doxylamine succinate, dicyclomine hydrochloride and pyridoxine hydrochloride (Debendox/Bendectin) prescribed to pregnant women. The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC), a case-control investigation has analysed data derived from interview reports and medical records of 555 mothers of children (under 15 years) with cancer and 1110 mothers of matched control children. Separate analyses of interview reports and medical records both suggested that antiemetic ingestion during the index pregnancy does not increase the risk of developing childhood malignant disease in the exposed foetus. No dose-response relationship was evident. The lack of any significant relative risks held good for diagnostic sub-groups and when the trimester of ingestion was considered. Our results suggest that antimetics of this type are unlikely to be transplacental carcinogens.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAdolescent
dc.subject.meshAntiemetics
dc.subject.meshChild
dc.subject.meshCyclohexanecarboxylic Acids
dc.subject.meshDicyclomine
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDoxylamine
dc.subject.meshDrug Combinations
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.subject.meshPregnancy
dc.subject.meshPregnancy Complications
dc.subject.meshPrenatal Exposure Delayed Effects
dc.subject.meshPyridines
dc.subject.meshPyridoxine
dc.subject.meshRisk
dc.titleInter-Regional Epidemiological Study of Childhood Cancer (IRESCC): childhood cancer and the consumption of debendox and related drugs in pregnancy.en
dc.typeArticleen
dc.contributor.departmentDepartment of epidemiology, Yorkshire Regional Cancer Organisation, Cookridge Hospital, Leeds LS16 6QBen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractAttention has recently focused on the possible teratogenic effects of the combination antiemetic doxylamine succinate, dicyclomine hydrochloride and pyridoxine hydrochloride (Debendox/Bendectin) prescribed to pregnant women. The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC), a case-control investigation has analysed data derived from interview reports and medical records of 555 mothers of children (under 15 years) with cancer and 1110 mothers of matched control children. Separate analyses of interview reports and medical records both suggested that antiemetic ingestion during the index pregnancy does not increase the risk of developing childhood malignant disease in the exposed foetus. No dose-response relationship was evident. The lack of any significant relative risks held good for diagnostic sub-groups and when the trimester of ingestion was considered. Our results suggest that antimetics of this type are unlikely to be transplacental carcinogens.


This item appears in the following Collection(s)

Show simple item record